Co-Diagnostics (NASDAQ:CODX) +176% on eliminating debt.Eyenovia (NASDAQ:EYEN) +52% on positive MicroStat data.Ekso Bionics Holdings (NASDAQ:EKSO) +33% on $100M JV to develop the...
Novavax (NASDAQ:NVAX) initiated with Outperform rating and $4 (87% upside) price target at Oppenheimer. Shares up 3% premarket.Synthetic Biologics (NYSEMKT:SYN) initiated with...
Lineage Cell Therapeutics, Inc. (NYSE:LCTX) has been struggling lately, but the selling pressure may be coming to an end soon. That is because LCTX recently saw a Hammer Chart...
Aytu BioScience, Inc. (NASDAQ:AYTU) was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more...
BioTime, Inc. (NYSE:BTX) was a big mover last session, as the company saw its shares rise 6% on the day. The move came on solid volume too with far more shares changing hands...
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing cell therapies for unmet medical needs. It is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. It has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is a cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.